Not a good buy right now for an impatient entry: price is slipping and momentum is weakening (bearish MACD expansion) while sitting just below a key support zone.
Options positioning is very call-skewed (bullish sentiment), but the stock still lacks a clean technical trigger today; downside to the next support remains plausible.
Wall Street view recently turned more constructive (new Buy coverage with a high target), but near-term fundamentals are still weak (revenue and gross margin down).
Technical Analysis
Trend/MAs: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests the broader trend has been constructive.
Momentum: MACD histogram at -0.0305 and negatively expanding = bearish momentum is strengthening in the near term.
RSI: RSI_6 43.85 (neutral/soft) = not oversold; limited evidence of a washout bottom today.
Key levels: Current ~3.45 is just below S1 ~3.471 (near-term support). If weakness continues, S2 ~3.127 is the next notable downside area. Upside requires reclaiming Pivot ~4.029, then R1 ~4.587.
Pattern-based odds (provided): modest +1-day edge, but negative 1-week expectation (-1.85%) suggests near-term chop/down risk still dominates.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Open interest is extremely call-heavy (OI put/call 0.06; calls OI 12,364 vs puts OI 739) → sentiment skewed bullish/speculative.
Volume: Put/call volume ratio 0.43 (more calls than puts), but absolute volume is low (total volume 10), so the signal is sentiment-skewed but not strongly confirmed by heavy trading.
Volatility: 30D IV ~199% with IV percentile 74.4 → options are pricing big moves; market expects high event/biotech-style volatility.
Activity vs baseline: Today’s volume vs 30D avg 1.67 (uptick), but again off a small base.
Technical Summary
Sell
2
Buy
9
Positive Catalysts
Analyst catalyst: Craig-Hallum initiated Buy with a $10 price target (large implied upside vs ~$3.45).
Pipeline/valuation narrative (from analyst note): “proof-of-concept setup” into 2H 2026 readouts; valuation implying limited credit for ATI-052 ahead of Phase 1b.
Sentiment: Options open interest is heavily tilted to calls (bullish skew).
Event ahead: Next earnings scheduled 2026-02-25 (Pre-Market) could act as a volatility catalyst.
Neutral/Negative Catalysts
increases risk of a push toward ~3.
Fundamentals: Latest quarter shows declining revenue and sharply lower gross margin (quality of the top line deteriorating).
Financial Performance
Latest quarter: 2025/Q3
Revenue:$3.2999M, -24.09% YoY (contraction).
Net income:-$14.614M, improved +92.64% YoY (loss narrowed materially).
Recent trend: New coverage initiated on 2026-01-30 by Craig-Hallum: Buy, $10 PT (no other rating changes provided).
Wall Street pros (from the initiation): strong upside implied by PT; upcoming proof-of-concept setup into 2H 2026; market may be underpricing ATI-052 ahead of Phase 1b.
Wall Street cons (practical counterweights): near-term financial profile still weak (revenue/margin down), and the stock’s current tape/momentum is not confirming a clean entry today.
Influential/political trading check: No recent Congress trading data available; hedge fund and insider trends reported as Neutral.
Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is 9.25 USD with a low forecast of 6 USD and a high forecast of 16 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.390
Low
6
Averages
9.25
High
16
Current: 3.390
Low
6
Averages
9.25
High
16
Craig-Hallum
NULL -> Buy
initiated
$10
AI Analysis
2026-01-30
Reason
Craig-Hallum
Price Target
$10
AI Analysis
2026-01-30
initiated
NULL -> Buy
Reason
Craig-Hallum initiated coverage of Aclaris Therapeutics with a Buy rating and $10 price target.
Craig-Hallum
Adam Vogel
Buy
initiated
$10
2026-01-30
Reason
Craig-Hallum
Adam Vogel
Price Target
$10
2026-01-30
initiated
Buy
Reason
As previously reported, Craig-Hallum analyst Adam Vogel initiated coverage of Aclaris Therapeutics with a Buy rating and $10 price target. The firm cites a proof-of-concept setup into the second half of 2026 readouts and a valuation that still implies limited credit for ATI-052 ahead of Phase 1b data.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACRS
